Patients with early stage Alzheimer’s disease have a new treatment option. On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted traditional approval to lecanemab (Eisai/Biogen), brand name Leqembi, for patients confirmed to be in early stage Alzheimer’s disease with elevated amyloid beta. The treatment was granted accelerated approval in January 2023, but this is the first Alzheimer’s treatment to receive traditional approval that changes the underlying course of the disease.
Alzheimer’s is a progressive, degenerative and fatal brain disease, the most common cause of dementia. An estimated 6.7 million Americans age 65 and older are living with Alzheimer’s dementia. More than 11 million people act as caregivers of people with Alzheimer’s disease or other dementias.
Read the entire article HERE for more detailed information.
This information provided courtesy of Seniors Guide, by Annie Tobey